Who are the investors of CMPX

The investors of CMPX (Compass Therapeutics) include a mix of institutional and retail investors, with several significant investments having been made by institutional investors. Here are some key points regarding CMPX's investor base:

1. **Institutional Investors**:
- **Rovin Capital UT ADV** acquired a new stake in CMPX in the third quarter valued at approximately $25,000.
- **Cubist Systematic Strategies LLC** purchased a new stake in CMPX during the second quarter worth about $41,000.
- **SG Americas Securities LLC** increased its holdings in CMPX by 16.6% in the third quarter and now owns 38,665 shares valued at $71,000.
2. **Retail Investors**: The stock has been traded by retail investors, and the company's stock price has been influenced by both positive and negative news related to its clinical trials and financial updates.
3. **Short Interest**: As of June 30, 2025, there were 7,390,000 shares of CMPX sold short, which represents a significant amount of short interest. This can be an indicator of negative sentiment among some investors.
4. **Analyst Ratings**: The stock has received mixed analyst ratings, with some analysts rating it as a "Strong Buy" and others as a "Hold" or "Buy." The average 12-month price target among analysts is $13.20, which represents a significant upside potential from the current price.

Overall, CMPX's investor base includes a diverse group of investors, with institutional investors making significant stakes in the company. The retail investor base is also active, and the stock's performance is influenced by both positive and negative news related to the company's clinical trials and financial updates.